3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
4
Phase 3
1
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Motor Activity
12
Breast Neoplasms
9
Neoplasms
6
Leukemia, Myeloid, Acute
3
Prostatic Neoplasms
2
Patient Compliance
2
Neoplasm Metastasis
2
Fatigue
2
Depression
2
Colorectal Neoplasms
2
Brain Neoplasms
2
Weight Loss
1
Weight Gain
1
Smoking Cessation
1
Peripheral Nervous System Diseases
1
Overweight
1
Ovarian Neoplasms
1
Obesity
1
Neuroectodermal Tumors, Primitive
1
Medulloblastoma
1
Lung Neoplasms
1
Insulin Resistance
1
Infratentorial Neoplasms
1
Fallopian Tube Neoplasms
1
Disease
1
Cognitive Dysfunction
1
Cholangiocarcinoma
1
Carcinoma, Hepatocellular
1
Bone Metabolism Biomarkers
1
Body Weight Changes
1
Interventions
Memantine
2
lithium sulfate
1
lime
1
fasudil
1
XENP 1595
1
Ramipril
1
Methylphenidate
1
Lithium
1
Infliximab
1
Ibuprofen
1
Exercise
1
Cannabidiol
1
Behavior Therapy
1
Aspirin
1
Ashwagandha
1
Anticonvulsants
1
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Cognitive Dysfunction
×
Exercise
×
Clear all
NCT00495703
2017-04-04
TACTIC
Vanderbilt University Medical Center
Phase 2
Completed
64 enrolled